Member Info for HedgeHogarth

Fortunate to see some market data on Consumer Technology Re-commerce - looked very positive indeed and I'm sure is putting a smile on the face of MMAG CEO

It all about expectations.....

One year ago, I was feeling pretty much the same as I do now - excited at making that big step from pre-clinical to clinical Biotech.

The SP is now 2.35p, one year ago it was 1.3p

(So while it has been a terribly frustrating year, my portfolio is up significantly as a result of +80% growth in HEMO)

I'm not sure any of us know enough or are qualified enough to know whether any of the additional wait to start clinical trials was avoidable - my gut feel is very little. It is what it is.

Whilst I still feel the SP hugely undervalues Hemo; small companies across the board are undervalues given the state of the equity markets and economy in the last 2 years. Hemo have progressed in that year, 2 great updates on CBR and we now have Prevail on board. However, 1 year on, we still cannot be sure when trials will start.

The RNS this week though confirmed that Hemo are doing everything they can to meet their ambitious timelines - including spending incremental money to expedite things.

We should have 3-4 significant market proven catalysts within weeks - It will be these pivotal events that give this share the best chance of a re-rate, and a big one at that.

I hope, I pray, I think that it is just a matter of further patience and time for my loyalty to be rewarded.

And If I'm wrong - maybe I could earn some pocket money as a paid troll on LSE. I feel like I've learnt more than enough from those who have poisoned this board over the last 4 years.

The two most powerful warriors are patience and time. – Leo Tolstoy (War and Peace)

I imagine it may be a bit of placing churn

I'm past caring.

Maybe Bob's being paid, maybe he's not.

Maybe Bob is an expert in patent law, maybe he is not. Do I want to read about patents in the detail he shares, no I don't.

Rightly or wrongly I trust that the company will do everything it can to protects it's IP. If it is not successful with patent, I assume it will explore other ways to retains it - like the good Colonel's secret recipe.

I will make a dignified exit and leave this troubled forum to the rest of you.

Good luck to the good ones ,👍

IMO - apologies if i have offended anyone or got this wrong.

Bobssocks, Flecky, Bobcat, DSFlat

I imagine "Tim nice but dim" types working in the city - collaborating

I should have added - "im my opinion" and based on my personal observations and those of others

Says it all....

Bobcat - in his own words "Next time we are pumping"

Collective manipulation

Disgusting behaviour and very sad that it is allowed to go on - condoned by LSE

I imagine one day we will wake up and find that LSE forums are offline - pending full enquiry

I agree 100% with you HT

Micky - very few people think the same as you

Surely the RNS updates on CBR etc give you the confidence that this is very much a Hemo asset

Woodcut - a bit of patience and I have no doubt the price at which you missed selling at will come around again

Apologies - I meant a 12mth low given my analysis below.

And before you correct me - I think it touched 14.5, so give or take a 12mth low

Need?

DrDeo - not the first and you wont be the last to have a pop at the Vlad as CEO.

As I have said before, I'm a fan and like the fact that the CEO is the founder - with all the passion, commitment and drive that comes with it. Hemo is Vlad's obsession - and it's success will double up as Vlad's success. Him and his wife have a lot of skin in the game with c10% of the company - that cannot be said for all small businesses. Their future and their child's future is dependant on the commercial success of Hemogenyx.

Here's an interesting article i would recommend on Founders as CEOs - the suggestion is that Biotech founders tend to relinquish the reins at the 'point of commercialisation'. (Definition below)

https://alitamaseb.medium.com/founding-ceo-vs-hired-ceo-what-the-data-reveals-eaaf20b7616e

The commercialisation of a new product is considered the final stage of new product development (NPD). At this point production, distribution, marketing, sales, customer support, and other key functions are needed to ensure commercial success. For Biotech this could be seen as completion of Phase 3 or possibly during Ph 2 for some drugs and therapies

This stock is seemingly below the radar of many...

It's being trolled persistently to suppress any speculative buying...

It remains in an offer period - despite BT/Aurelius declaring themselves 'out'

The company has declared its intent to seek a buyer

The share price now sitting at an all time low

The only two parties that i see who benefit from the share price at this level; anyone with a short position and/or a prospective bidder negotiating on price.

Looking at industry averages from 2018/19 - a premium of 30-40% could be expected. (20-25p)

However, looking at recent acquisition - where company SPs have been battered down in the last 2 years of bear market:

Hotel Chocolat - Premium Paid - 170% (HOTC SP was 40% lower at point of ACQ vs 12m Peak)

On The Market - Premium Paid - 56% (OTM SP was 12% lower at point of ACQ vs 12m Peak)

The Restaurant Group - Premium Paid - 34% (OTM SP was 6% lower at point of ACQ vs 12m Peak)

Music Magpie - Premium Paid - TBC (MMAG SP would be 66% lower ACQ today vs 12m Peak)

Clear relationship between the Premium paid and the current state of the SP. I am confident that MMAG will find a buyer and expect the premium to be in the region of 150%

And just for clarity - It's only my opinion about what is happening. I'd love to know, but all i have to go by is the recent and historic RNSs the same as you

Who knows - but if it's just paperwork - its perfectly feasible to be a week. I've done consultancy work in a week before and achieved loads.

I'd also add that consultants I have worked with tend to work very long hours and be extremely productive. But maybe you are right, maybe it will take a month. However, this would make Vlad's comment about ambitious schedule seem a little strange and out of place would it not?

Based on my previous posts regarding runs (end to end including ALL testing) I am sticking to my opinion

Before you do you usual attack.

I'm not saying you are right or wrong. I'm just saying that neither of us know for sure and we just happen to have a difference of opinion

Good day to you

HT - you do not know that. It is purely your opinion,

As it happens, my opinion is different - I do not know either, my i would suspect the manufacturing run is probably complete now.

However, we do agree that the IND submission as not happened yet. But we don't know how long it will take and Vlad talked about accelerating it with funds from the placing. My guess is that he brought in a specialist contractor to help with the submission.

Maybe you should read the RNS Pumpky: Today's Placing will enable the Company to progress with its ambitious schedule to move forward to clinical trials

Feel free to point me in the direction of any schedule share by Hemo other than in their RNS on 18th Sept:

"Prevail InfoWorks, Inc. to act as Contract Research Organization (CRO) for upcoming Phase I clinical study, expected to commence in 2023

Personally, writing as i am on 29th November, these does feel ambitious - but still doable if you think the FDA may not take the whole 30 days